Lasry, A., Zinger, A. & Ben-Neriah, Y. Inflammatory networks underlying colorectal cancer. Nat. Immunol. 17, 230–240 (2016).
Farraye, F. A., Odze, R. D., Eaden, J. & Itzkowitz, S. H. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 138, 746–774, 774.e1–774.e4; quiz e12–e13 (2010).
Chan, A. T. et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 294, 914–923 (2005).
Chan, A. T. et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 134, 21–28 (2008).
Baron, J. A. et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 348, 891–899 (2003).
Sandler, R. S. et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 348, 883–890 (2003).
Arber, N. et al. Celecoxib for the prevention of colorectal adenomatous polyps. N. Engl. J. Med. 355, 885–895 (2006).
Bertagnolli, M. M. et al. Celecoxib for the prevention of sporadic colorectal adenomas. N. Engl. J. Med. 355, 873–884 (2006).
Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
Cruz, M. D. et al. Metabolic reprogramming of the premalignant colonic mucosa is an early event in carcinogenesis. Oncotarget 8, 20543–20557 (2017).
Deng, T., Lyon, C. J., Bergin, S., Caligiuri, M. A. & Hsueh, W. A. Obesity, inflammation, and cancer. Annu. Rev. Pathol. 11, 421–449 (2016).
Yehuda-Shnaidman, E. & Schwartz, B. Mechanisms linking obesity, inflammation and altered metabolism to colon carcinogenesis. Obes. Rev. 13, 1083–1095 (2012).
Jiao, L. et al. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer Epidemiol. Biomarkers Prev. 20, 1430–1438 (2011).
Song, M. et al. A prospective study of plasma inflammatory markers and risk of colorectal cancer in men. Br. J. Cancer 108, 1891–1898 (2013).
Aleksandrova, K. et al. Biomarker patterns of inflammatory and metabolic pathways are associated with risk of colorectal cancer: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Eur. J. Epidemiol. 29, 261–275 (2014).
Mehta, R. S. et al. A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer. J. Natl. Cancer Inst. 106, dju016 (2014).
Chen, L. et al. A prospective study of soluble receptor for advanced glycation end-products and colorectal cancer risk in postmenopausal women. Cancer Epidemiol. 42, 115–123 (2016).
Chan, A. T., Ogino, S., Giovannucci, E. L. & Fuchs, C. S. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 140, 799–808 (2011). quiz e11.
Izano, M. et al. Chronic inflammation and risk of colorectal and other obesity-related cancers: The health, aging and body composition study. Int. J. Cancer 138, 1118–1128 (2016).
Ma, J. et al. A prospective study of plasma levels of insulin-like growth factor I (IGF-I) and IGF-binding protein-3, and colorectal cancer risk among men. Growth Horm. IGF Res. 10(Suppl A), S28–S29 (2000).
Gao, Y. et al. SerumIGF1, IGF2 and IGFBP3 and risk of advanced colorectal adenoma. Int. J. Cancer 131, E105–E113 (2012).
Davenport, J. R. et al. Evaluation of pro-inflammatory markers plasma C-reactive protein and urinary prostaglandin-E2 metabolite in colorectal adenoma risk. Mol. Carcinog. 55, 1251–1261 (2016).
Hundt, S., Haug, U. & Brenner, H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann. Intern. Med. 150, 162–169 (2009).
Haug, U., Hundt, S. & Brenner, H. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am. J. Gastroenterol. 105, 682–690 (2010).
Brenner, H., Tao, S. & Haug, U. Low-dose aspirin use and performance of immunochemical fecal occult blood tests. JAMA 304, 2513–2520 (2010).
Assarsson, E. et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS ONE 9, e95192 (2014).
Enroth, S., Johansson, A., Enroth, S. B. & Gyllensten, U. Strong effects of genetic and lifestyle factors on biomarker variation and use of personalized cutoffs. Nat. Commun. 5, 4684 (2014).
Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118–127 (2007).
Degirolamo, C., Sabba, C. & Moschetta, A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat. Rev. Drug Discov. 15, 51–69 (2016).
Youm, Y. H., Horvath, T. L., Mangelsdorf, D. J., Kliewer, S. A. & Dixit, V. D. Prolongevity hormone FGF21 protects against immune senescence by delaying age-related thymic involution. Proc. Natl Acad. Sci. USA 113, 1026–1031 (2016).
Feng, W., Dryden, G. & McClain, C. Fibroblast growth factor 21 depletion attenuates acute experimental colitis in mice through epithelial STAT3 activation. FASEB J. 31(1_supplement), 995.1 (2017).
Yang, C. et al. Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress. BMC Gastroenterol. 13, 67 (2013).
Bhalla, K. et al. PGC1alpha promotes tumor growth by inducing gene expression programs supporting lipogenesis. Cancer Res. 71, 6888–6898 (2011).
Vazquez, A. et al. Cancer metabolism at a glance. J. Cell Sci. 129, 3367–3373 (2016).
Akyol, M. et al. The alterations of serum FGF-21 levels, metabolic and body composition in early breast cancer patients receiving adjuvant endocrine therapy. Cancer Biomark. 18, 441–449 (2017).
Knott, M. E. et al. Levels of fibroblast growth factor 21 (FGF21) in serum as diagnostic biomarker in patients with breast cancer [abstract]. Cancer Res 75(15 Suppl), 1577 (2015).
Harlid, S., Myte, R. & Van Guelpen, B. The metabolic syndrome, inflammation, and colorectal cancer risk: an evaluation of large panels of plasma protein markers using repeated, prediagnostic samples. Mediat. Inflamm. 2017, 4803156 (2017).
Stemmer, K. et al. FGF21 is not required for glucose homeostasis, ketosis or tumour suppression associated with ketogenic diets in mice. Diabetologia 58, 2414–2423 (2015).
Tao, S., Hoffmeister, M. & Brenner, H. Development and validation of a scoring system to identify individuals at high risk for advanced colorectal neoplasms who should undergo colonoscopy screening. Clin. Gastroenterol. Hepatol. 12, 478–485 (2014).
Weigl, K. et al. Strongly enhanced colorectal cancer risk stratification by combining family history and genetic risk score. Clin. Epidemiol. 10, 143–152 (2018).
Kim, S. et al. Circulating levels of inflammatory cytokines and risk of colorectal adenomas. Cancer Res. 68, 323–328 (2008).
Il’yasova, D. et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol. Biomarkers Prev. 14, 2413–2418 (2005).
Song, M. et al. Plasma inflammatory markers and risk of advanced colorectal adenoma in women. Cancer Prev. Res. (Phila) 9, 27–34 (2016).
Waugh, D. J. & Wilson, C. The interleukin-8 pathway in cancer. Clin. Cancer Res. 14, 6735–6741 (2008).
Jin, W. J., Xu, J. M., Xu, W. L., Gu, D. H. & Li, P. W. Diagnostic value of interleukin-8 in colorectal cancer: a case-control study and meta-analysis. World J. Gastroenterol. 20, 16334–16342 (2014).
Dressen, K. et al. Diagnostic performance of a novel multiplex immunoassay in colorectal cancer. Anticancer Res. 37, 2477–2486 (2017).